

REMARKS

Claims 1-31 are pending in the application.

The Abstract has been amended to remove legal terminology.


Claim 7 has been amended to include in its recitation that antibodies comprising SEQ ID NO:5 specifically bind the IGF-I receptor. Support for the amendment may be found throughout the specification, such as in paragraph 62.

The claims have been amended to recite the "epitope-binding" fragment of antibodies. Support for the amendment may be found in paragraphs 69 and 74 where it is stated that functional equivalents are included within the scope of the invention, and that antibody fragments having the same binding characteristics as the whole antibody are functional equivalents.

The claims have also been amended to specify that the antibodies and antibody fragments of the present invention comprise particular heavy chain and light chain "variable regions." Support for the amendment can be found throughout the specification, such as in paragraphs 19, 20, 25 and 26, and in claims 15 and 16.

Entry and consideration of this Amendment are respectfully requested.

Respectfully submitted,



Drew Hisson
Registration No. 44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: August 3, 2005